A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment

Trial Profile

A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Bendamustine
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; MALT lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Acronyms COMPLEMENT A+B
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 25 May 2017 Planned primary completion date changed from 17 Apr 2017 to 30 Aug 2017.
    • 05 Apr 2017 Planned primary completion date changed from 1 Jul 2023 to 17 Apr 2017.
    • 05 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top